COMMUNIQUÉS West-GlobeNewswire

Helsinn Therapeutics (U.S.) Inc., Signs Co-Promotion Agreement for Cancer Therapeutic Zykadia® in the US

05/09/2017 - 14:15

Helsinn Therapeutics (U.S.) Inc., Signs Co-Promotion Agreement for Cancer Therapeutic Zykadia ® in the US Zykadia ® (ceritinib) is an approved treatment for patients with metastatic non-small cell lung cancer (NSCLC) [...]

Minerva Neurosciences Announces Enrollment of First Patient in Phase 2b Trial of Seltorexant (MIN-202) as Adjunctive Therapy in Patients With Major Depressive Disorder

05/09/2017 - 14:00

WALTHAM, Mass., Sept. 05, 2017 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ:NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system (CNS) [...]

Auris Medical to Host Scientific Symposium at the AAO-HNSF Annual Meeting

05/09/2017 - 14:00

ZUG, Switzerland, Sept. 5, 2017 (GLOBE NEWSWIRE) -- Auris Medical Holding AG (NASDAQ: EARS), a clinical-stage company dedicated to developing therapeutics that address important unmet medical needs in otolaryngology, [...]

Apricus Biosciences to Present at the Rodman & Renshaw 19th Annual Global Investment Conference

05/09/2017 - 13:00

SAN DIEGO, Sept. 05, 2017 (GLOBE NEWSWIRE) -- Apricus Biosciences, Inc. (Nasdaq:APRI), a biopharmaceutical company advancing innovative medicines in urology and rheumatology, today announced that Richard W. Pascoe, [...]

Summit Therapeutics plc : Positive Top-line Phase 2 Results

05/09/2017 - 13:00

Summit Therapeutics plc ('Summit' or the 'Company') SUMMIT ANNOUNCES POSITIVE TOP-LINE DATA FROM AN EXPLORATORY PHASE 2 CLINICAL TRIAL SUPPORTING RIDINILAZOLE AS A HIGHLY SELECTIVE ANTIBIOTIC FOR THE TREATMENT OF CDI [...]

Helsinn Investment Fund: MAL Therapeutics raises €8 million (CHF 8.8 million) in first closing of Series B financing round

05/09/2017 - 10:10

AMAL Therapeutics raises €8 million (CHF 8.8 million) in first closing of Series B financing round Financing round co-led by Boehringer Ingelheim Venture Fund, BioMedPartners and Helsinn Investment Fund Funds will be [...]

Ascom appoints Ljubisav Matejevic as Vice President Global Ecosystem & Central and Eastern Europe

05/09/2017 - 10:08

Ascom strengthens its management team by appointing Ljubisav Matejevic as Vice President Global Ecosystem & Central and Eastern Europe (CEE). He will be responsible for Sales Team Leadership, Market Development and [...]

Zealand Pharma to present at Morgan Stanley Global Healthcare Conference in New York on September 12, 2017

05/09/2017 - 10:01

Company announcement - No. 44 / 2017 Zealand Pharma to present at Morgan Stanley Global Healthcare Conference in New York on September 12, 2017 Copenhagen, September 5, 2017 - Britt Meelby Jensen, President and Chief [...]

Glasses go 'bio'. Partnership between Bio-on and Kering Eyewear.

05/09/2017 - 08:00

The two companies will work together on new eco-sustainable materials to match and exceed the characteristics of the plastics used to date in eyewear The aim is to create a series of innovative materials to broaden [...]

Les lunettes deviennent «bio». Avènement d'un partenariat entre Bio-on et Kering Eyewear.

05/09/2017 - 08:00

Les deux entreprises étudieront ensemble de nouveaux matériaux éco-durables, dont les caractéristiques sont comparables, voire supérieures, à celles des matières plastiques utilisées jusqu'à présent dans le secteur de [...]

Novartis landmark Phase III trial shows fingolimod significantly reduces relapses in children and adolescents with MS

05/09/2017 - 07:15

Phase III PARADIGMS study in pediatric MS met its primary endpoint, showing a significant reduction in relapses occur with fingolimod versus interferon beta-1a There is a significant unmet need for safe and effective MS [...]

TiGenix obtains commercial production license for expanded manufacturing facility

05/09/2017 - 07:00

PRESS RELEASE TiGenix obtains commercial production license for expanded manufacturing facility - Provides capacity for potential European commercial roll out of investigational stem cell therapy, Cx601 - Expanded [...]

TiGenix obtient la licence de production commerciale pour son centre de fabrication élargi

05/09/2017 - 07:00

COMMUNIQUÉ DE PRESSE TiGenix obtient la licence de production commerciale pour son centre de fabrication élargi - Le centre a une capacité suffisante pour la commercialisation éventuelle en Europe du Cx601, une thérapie [...]

Biocartis Group NV: Idylla(TM) Respiratory (IFV-RSV) Panel receives 510(k) clearance by US FDA

05/09/2017 - 07:00

PRESS RELEASE: 5 September 2017, 07:00 CEST Idylla(TM) Respiratory (IFV-RSV) Panel receives 510(k) clearance by US FDA First test cleared for use on the Idylla(TM) platform by US FDA Mechelen, Belgium, 5 September 2017 [...]

Santhera Announces Financial Results for the First Half-Year 2017 and Reports Commercial and Development Progress

05/09/2017 - 07:00

Liestal, Switzerland, September 5, 2017 - Santhera Pharmaceuticals (SIX: SANN) reports first half-year results as of June 30, 2017: 1H 2017 sales of CHF 10.9 million, increase of 51% compared to 1H 2016 Successful [...]

Les données publiées dans The Lancet montrent des résultats positifs au niveau du terminal primaire dans le traitement de l'hypertension résistante avec le dispositif MobiusHD

05/09/2017 - 01:51

Cette publication fait suite aux résultats intermédiaires positifs chez les patients des États-Unis et de l'UE présentés lors de la conférence de la Société européenne de cardiologie MOUNTAIN VIEW, Californie, le 1 er [...]

Sanofi: Disclosure of trading in own shares

04/09/2017 - 18:00

Disclosure of trading in own shares This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients. The issuer of this announcement warrants that they are solely [...]

Sanofi : Déclaration des transactions sur actions propres

04/09/2017 - 18:00

Déclaration des transactions sur actions propres This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients. The issuer of this announcement warrants that they are [...]

NICOX : Nombre de droits de vote au 31 août 2017

04/09/2017 - 17:30

Nicox SA Société anonyme au capital de 29 169 338 euros Siège social : DRAKKAR D 2405 route des Dolines 06560 Valbonne Sophia-Antipolis R.C.S. GRASSE 403.942.642 Le 4 septembre 2017, PUBLICATION MENSUELLE DU NOMBRE D' [...]